ROCKVILLE, Md. – June 6, 2024 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published a set of evidence-based recommendations for ...
Association for Molecular Pathology publishes best practice recommendations for clinical HRD testing
ROCKVILLE, Md. – June 24, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, today announced the publication of best practice recommendations ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
MISSISSAUGA, ON / ACCESS Newswire / February 4, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is ...
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment ...
Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.
When patients develop a narrowing or blockage in the bile ducts—the tubes connecting the liver, gallbladder and intestines—physicians must determine whether the cause is cancer or a benign condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results